| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥52.5B | ¥50.6B | +3.7% |
| Operating Income | ¥3.0B | ¥2.6B | +13.6% |
| Ordinary Income | ¥3.1B | ¥2.7B | +13.9% |
| Net Income | ¥2.2B | ¥1.6B | +36.4% |
| ROE | 8.1% | 6.3% | - |
FY2026 Q3 results show moderate growth across all profit lines. Revenue reached 5,249 million yen (YoY +3.7%), Operating Income 298 million yen (YoY +13.6%), Ordinary Income 310 million yen (YoY +13.9%), and Net Income 218 million yen (YoY +36.4%). The company maintained a high gross profit margin of 56.6% while demonstrating improved operating leverage through controlled selling, general and administrative expenses. Net income growth significantly outpaced revenue growth, driven by stable non-operating performance and lower tax burden. The balance sheet expanded to 5,490 million yen in total assets from 5,060 million yen, with equity increasing to 2,710 million yen from 2,530 million yen. Earnings per share reached 20.44 yen for the quarter, while the company forecasts full-year revenue of 6,320 million yen with net income of 75 million yen, representing projected annual growth of 66.1% in net income.
[Profitability] ROE of 8.1% is calculated from net profit margin of 4.2%, total asset turnover of 0.956, and financial leverage of 2.03 times based on DuPont analysis. Operating margin improved to 5.7% for the period, supported by gross profit margin of 56.6%, indicating strong pricing power and product mix advantages. Interest coverage ratio stands at approximately 30 times, with interest expense of 10 million yen against operating income of 298 million yen, demonstrating ample capacity to service debt obligations. [Cash Quality] Cash and deposits totaled 1,395 million yen, providing coverage of 1.70 times against short-term debt of 820 million yen. Working capital shows deterioration with accounts receivable increasing 43.0% YoY to 838 million yen, and inventory turnover days extended to 96 days, suggesting collection and inventory management challenges. [Investment Efficiency] Total asset turnover of 0.956 reflects moderate asset utilization. Receivables turnover days lengthened significantly due to the 43.0% increase in accounts receivable against 3.7% revenue growth, warranting attention to collection efficiency. [Financial Health] Equity ratio stands at 49.4%, down from 50.0% in the prior year, with current ratio of 182.9% and quick ratio of 150.5% indicating solid short-term liquidity. Debt-to-equity ratio of 1.03 remains within conservative range, though short-term debt represents 61.2% of total liabilities at 820 million yen, creating refinancing concentration risk. Interest-bearing debt totals 1,340 million yen, comprising 820 million yen in short-term borrowings and 520 million yen in long-term debt.
Cash and deposits decreased 51 million yen YoY from 1,446 million yen to 1,395 million yen despite net income growth of 36.4%, indicating cash consumption in working capital. The primary driver of cash usage appears to be accounts receivable expansion of 252 million yen (43.0% YoY increase), significantly outpacing revenue growth and suggesting extended payment terms or customer mix changes. Accounts payable increased 68 million yen (27.8% YoY) to 313 million yen, providing partial offset through supplier credit utilization. Long-term borrowings increased 140 million yen (36.8% YoY) to 520 million yen, suggesting debt refinancing or funding for capital allocation. Short-term debt coverage by cash remains adequate at 1.70 times, though the combination of cash decline and working capital expansion indicates potential pressure on operating cash generation. The working capital cycle shows deterioration with inventory turnover at 96 days and receivables collection extending significantly, both factors constraining cash conversion despite profitable operations.
Ordinary income of 310 million yen compared to operating income of 298 million yen indicates net non-operating contribution of approximately 12 million yen, representing 0.2% of revenue. Non-operating income totaled 22 million yen, primarily consisting of dividend income and other financial income, while non-operating expenses included interest expense of 10 million yen, resulting in modest net financial income contribution. The non-operating impact is minimal relative to core operating performance, suggesting earnings quality is driven predominantly by business operations. The significant divergence between net income growth of 36.4% and operating income growth of 13.6% reflects lower effective tax burden, with the tax burden coefficient at 0.694. The substantial increase in accounts receivable (43.0% YoY) against moderate revenue growth (3.7% YoY) raises concerns about accruals quality, as revenue recognition may be outpacing cash collection. Inventory turnover days of 96 days combined with receivables expansion suggests working capital is absorbing cash that would otherwise validate reported earnings. While the interest coverage ratio of 30 times demonstrates strong debt servicing capacity, the deterioration in working capital metrics warrants monitoring of cash-backed earnings quality in future periods.
Working capital deterioration poses the primary risk, with accounts receivable surging 43.0% YoY to 838 million yen while revenue grew only 3.7%, and inventory turnover extending to 96 days. This 252 million yen increase in receivables represents 115% of quarterly net income, indicating potential collection challenges or aggressive revenue recognition that could pressure future cash flows and require additional financing. Short-term debt concentration creates refinancing risk, with 820 million yen in short-term borrowings representing 61.2% of total liabilities and requiring rollover within one year. While current cash coverage of 1.70 times appears adequate, deteriorating operating cash generation could elevate refinancing vulnerability if credit conditions tighten. Operating margin of 5.7% and net profit margin of 4.2% remain below pharmaceutical industry best practices, limiting buffer against adverse events. The low profitability combined with ROE of 8.1% suggests constrained pricing power in certain segments or cost structure challenges that could impair competitiveness during market downturns or regulatory changes affecting pharmaceutical pricing and reimbursement.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates significantly stronger performance than pharmaceutical industry medians across multiple dimensions. Profitability metrics substantially exceed industry benchmarks, with Operating Margin of 5.7% versus industry median of -218.2%, Net Profit Margin of 4.2% versus industry median of -216.8%, and ROE of 8.1% versus industry median of -35.8%. This positions the company in the upper quartile of pharmaceutical peers, most of which reported losses during the same period. Financial Health indicators show Equity Ratio of 49.4% below the industry median of 67.8%, suggesting more aggressive use of leverage compared to peers, though still within prudent ranges. Current Ratio of 182.9% falls well below the industry median of 662%, reflecting the company's higher proportion of current liabilities at 61.2% of total liabilities. Efficiency metrics reveal Asset Turnover of 0.956 substantially exceeds the industry median of 0.17, indicating superior asset utilization, while Receivables Turnover Days of approximately 58 days (calculated from 838 million yen receivables and quarterly revenue) compares favorably to industry median of 151.55 days despite recent deterioration. Revenue Growth of 3.7% YoY contrasts sharply with industry median decline of -12.5%, demonstrating relative market share gains or better demand resilience. The company's positive profitability, revenue growth, and efficient asset utilization distinguish it from an industry cohort characterized by widespread losses and revenue contraction. (Industry: Pharmaceutical, N=13 companies for most metrics, Comparison period: 2025-Q3, Source: Proprietary analysis)
Gross profit margin sustainability at 56.6% represents a key structural advantage, indicating differentiated product positioning or favorable customer contracts that generate premium margins significantly above typical pharmaceutical distribution businesses. This high gross margin provides operating leverage potential, as evidenced by operating income growing 13.6% on revenue growth of only 3.7% through controlled SG&A expenses. The margin structure suggests the Retail and Water Operation divisions contribute disproportionately to profitability, with the Wholesaling Division reporting negative operating income of 4.4 million yen requiring strategic review. Working capital management emerges as the critical near-term determinant of cash flow performance and financial flexibility. The 252 million yen increase in accounts receivable and extended inventory turnover to 96 days collectively represent approximately 350 million yen in incremental working capital consumption, exceeding full-year forecasted net income of 75 million yen. Resolution of working capital efficiency through improved collection processes or inventory optimization would significantly enhance free cash flow generation and reduce dependence on short-term borrowing. Conservative full-year guidance projects net income of 75 million yen against 218 million yen already achieved in Q3 cumulative results, implying potential for upside revision or reflecting seasonal patterns and one-time factors in quarterly results requiring clarification. The disconnect between quarterly run-rate and annual forecast, combined with 66.1% projected annual net income growth, suggests either conservative forecasting or material profit variability across quarters that investors should monitor through segment disclosures and management commentary.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.